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Objective: The clinical significance and treatment of retrograde collateral arterial perfusion of abdominal aortic aneurysms after
endovascular repair (type II endoleak) have not been completely characterized. A canine abdominal aortic aneurysmmodel of type
II endoleak with an implanted pressure transducer was used to evaluate the use of polyurethane foam to induce thrombosis of type
II endoleaks. The effect on endoleak patency, intra-aneurysmal pressure, and thrombus histology was studied.
Methods:Prosthetic aneurysmswithan intraluminal, solid-state, strain-gaugepressure transducerwere created in the infrarenal aorta
of 14mongrel dogs. Aneurysm side-branch vessels were reimplanted into the prosthetic aneurysm of 10 animals by using a Carrel
patch. Type II (retrograde) endoleakswere created by excluding the aneurysm fromantegrade perfusionwith an impermeable stent
graft. Thrombosis of the type II endoleak was induced by implantation of polyurethane foam into the prosthetic aneurysm sac of
four animals. Six animals with type II endoleaks were not treated. In four control animals, no collateral side branches were
reimplanted, and therefore no endoleakwas created. Intra-aneurysmal and systemic pressuresweremeasureddaily for 60 to90days
after the implantation of the stent graft. Endoleak patency and flowwere assessed during surgery and at the time of death by using
angiographic imaging and duplex ultrasonography. Histologic analysis of the intra-aneurysmal thrombus was also performed.
Results: Intra-aneurysmal pressure values are indexed to systemic pressure and are represented as a percentage of the simultaneously
obtained systemic pressure, which has a value of 1.0. All six animals with untreated type II endoleaks maintained patency of the
endoleak and side-branch arteries throughout the study period. Compared with control aneurysms that had no endoleak, animals
with patent type II endoleaks exhibited significantly higher intra-aneurysmal pressurization (systolic pressure: patent type II
endoleak, 0.702 0.283; control, 0.172 0.091; P< .001; mean pressure: endoleak, 0.784 0.229; control, 0.137 0.102; P
< .001; pulse pressure: endoleak, 0.406 0.248; control, 0.098 0.077; P< .001; P< .001 for comparison for all groups by
analysis of variance). Treatment of the type II endoleak with polyurethane foam induced thrombosis of the endoleak and feeding
side-branch arteries in all four animalswith type II endoleaks. This resulted in intra-aneurysmal pressures statistically indistinguish-
able fromthe controls (systolic pressure, 0.1830.08;meanpressure, 0.1420.09; pulse pressure, 0.0540.04; not significant).
Angiography and histology documented persistent patency up to the time of death (mean, 64 days) for untreated type II endoleaks
and confirmed thrombosis of polyurethane foam–treated endoleaks in all cases.
Conclusions: Untreated type II endoleaks were associated with intra-aneurysmal pressures that were 70% to 80% of systemic
pressure.Treatmentwithpolyurethane foamresulted inareductionof intra-aneurysmalpressure toa level thatwas indistinguishable
from control aneurysms that had no endoleak. (J Vasc Surg 2005;42:321-8.)
Clinical Relevance: Endovascular repair of abdominal aortic aneurysms is dependent on the successful exclusion of the aneurysm
from arterial circulation. Type II endoleaks originate from retrograde flow into the aneurysm sac. This study demonstrates the use
of polyurethane foam to induce thrombosis in a caninemodel of a type II endoleak, thereby reducing intra-aneurysmal pressure to
levels similar to levels in animals without endoleaks. This approach may be a strategy for future treatment of type II endoleaks.From the Departments of Surgerya and Radiology,b New York Presbyterian
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aortic aneurysms (AAAs) is dependent on exclusion of the
aneurysm from the arterial circulation.1 Exclusion elimi-
nates arterial flow and systemic pressure from the aneurysm
sac, thus preventing continued aneurysm expansion and
rupture. After endovascular treatment, continued arterial
perfusion of the aneurysm sac may compromise the effec-
tiveness of endovascular aneurysm repair; incomplete ex-
clusion has been reported to occur in 14% to 29% of
patients treated in clinical trials.2-6 This continued arterial
perfusion has been termed endoleak and may be broadly
categorized as originating from either a direct antegrade or
a retrograde collateral source.7,8
Endoleaks that originate from retrograde flow through
aneurysm side-branch arteries (type II endoleak) are of
indeterminate significance.9-11 Furthermore, the pressure
and force associated with type II endoleaks have been
incompletely characterized.12,13 The risk of continued an-
eurysm expansion and aneurysm rupture remains contro-
versial.14-16 Consequently, definitive conclusions regard-
ing the risks and management of retrograde endoleaks have
yet to be established. Some authors advocate early interven-
tion, whereas others suggest continued observation.
Polyurethanes have quickly been integrated into re-
search and development in various medical fields. Polyure-
thane is highly biocompatible and has been widely used in
the construction of hematology-related products and de-
vices, such as catheters, pacemaker leads, heart valves,
wound dressings, and facial reconstruction implants.17
Polyurethane foam (PUF) provides a size-controlled scaf-
fold to which cells adhere and organize and therefore has
become a well-established matrix for cartilage tissue engi-
neering.18 This morphology also facilitates vascularized
Fig 1. Schematic diagram of retrograde (type II) endoleak treat-
ment. A, The prosthetic aneurysm (A) is sewn as an interposition
graft in the infrarenal aorta. Paired lumbar arteries are reimplanted
onto the aneurysm as a Carrel patch. The strain-gauge pressure
transducer (T) enables intra-aneurysmal pressure determination.
B,The retrograde (type II) endoleak is created by deploying a stent
graft (SG) coaxially through the aneurysm to exclude it from
antegrade perfusion. C, Polyurethane foam (PUF) is implanted
into the aneurysm sac at the same setting once the distal end of the
SG has been deployed through the endovascular graft (EVG)
catheter. The PUF delivery catheter is positioned within the aneu-
rysm sac before deployment of the stent graft and is withdrawn
after deployment.tissue ingrowth into the interior of the scaffold, thus en-gendering biological fixation of the implant and, ulti-
mately, occlusion of the targeted vascular site or space.19-21
The use of PUF to induce thrombosis is currently being
evaluated for potential clinical applications.
In this study, a canine AAA model was used to study
PUF as a treatment option for persistent type II en-
doleaks by inducing thrombus formation within the
aneurysm sac. PUF effectiveness was assessed by measur-
ing intra-aneurysmal pressure before aneurysm exclusion
and after endovascular repair and PUF implantation.
MATERIALS AND METHODS
Aneurysm model. Prosthetic aneurysms were created
in the infrarenal aorta of 14 mongrel dogs. All animals were
treated in accordance with theGuide for the Care andUse of
Laboratory Animals formulated by the Institute of Labora-
tory Animal Resources, Commission on Life Sciences.22
Animals weighed 25 to 30 kg. Type II endoleaks were
created in 10 animals by reimplanting 2 lumbar arteries by
using a Carrel patch, as described below. Subsequent ex-
clusion of the aneurysm by using a stent graft generated
type II endoleaks in six animals. In four distinct animals,
type II endoleaks were created in an identical fashion. The
type II endoleaks in these four animals were then treated by
filling the aneurysm sac outside the stent graft with PUF in
the manner detailed below. In four additional animals, no
side branches were implanted onto the aneurysm. These
animals served as controls and had no endoleak.
After the induction of general anesthesia (induction,
thiopental 8 mg/kg intravenously; maintenance, isoflurane
2%), transabdominal exposure of the aorta was performed.
Systemic anticoagulation (unfractionated sodium heparin,
2000 U intravenously) was maintained throughout the
period of arterial clamping. The prosthetic aneurysm con-
taining the intraluminal pressure transducer was implanted
as an interposition graft in the infrarenal aorta (Fig 1).
Prosthetic aneurysms were created by balloon dilation
of an 8-mm polytetrafluoroethylene (PTFE) conduit (Im-
pra; Bard Corp, Tempe, Ariz) to a final diameter of 30 mm.
The PTFE material was not altered, and no layers of the
graft were removed before dilation with the balloon. Two
lumbar arteries were re-implanted onto the posterior aspect
of the aneurysm by using a Carrel patch technique (Fig 2).
The lumbar vessels were carefully handled to minimize the
risk of vasospasm or intimal injury.
An implantable, solid-state, strain-gauge pressure
transducer (Konigsberg Instruments, Pasadena, Calif) was
used for chronic in vivo monitoring of systemic and intra-
aneurysmal pressure. The accuracy of the transducer has
been confirmed in various media in vitro and in vivo,
including liquid, gelatinous, and solid environments.23,24
Additionally, the transducer has been demonstrated to be
highly accurate in measuring pressure in a wide range of
physiological applications, including the heart and cecum.
This transducer was selected for its ability to accurately
assess intra-aneurysmal pressure in the presence of throm-
bus.23 The transducer has been shown to provide more
accurate measurements in semisolid material, such as
magn
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Continuous pressure monitoring and data storage were
performed with data-recording software from Data Inte-
grated Scientific Systems (Detroit, Mich). Before implan-
tation and after explantation, calibration of the transducer
was performed. At the time of aneurysm creation, the
pressure transducer was sewn to the luminal surface of the
prosthetic aneurysm. Of note, because a single transducer
was used, any variation in pressure with location in the
aneurysm sac could not be accounted for.
The cable from the pressure transducer was tunneled
laterally through the abdominal wall and tracked subcuta-
neously to exit the skin between the scapulae. A second
strain-gauge pressure transducer (Konigsberg) was used to
measure systemic pressure; it was placed in the native aorta
proximal to the aneurysm and tunneled along a parallel
course, exiting the skin adjacent to the first transducer. To
allow the transducer sites to heal and to prevent manipula-
tion by the animal, a protective collar was used after sur-
gery. Measurements from both transducers were obtained
simultaneously to allow comparison of intra-aneurysmal
pressure and systemic arterial pressure.
Intra-aneurysmal pressure determinations were made
daily for 2 weeks. During this time, clopidogrel (75 mg/d)
was administered to animals whose aneurysms had side
branches, to facilitate patency of the lumbar artery im-
plants. Exclusion of the aneurysm sac from antegrade per-
fusion was then performed transarterially via femoral cut-
down with a PTFE stent graft (Viabahn endoprosthesis;
W. L. Gore, Flagstaff, Ariz). Open operative exposure of
the femoral arteries was used. Two 8-mm  5-cm endo-
prostheses were then deployed in an overlapping fashion
through a 9F sheath and under fluoroscopic guidance.
Continued patency and retrograde flow in the aneurysm
side-branch arteries were confirmed by angiography per-
formed through the contralateral femoral artery. In 6 of the
10 animals with side branches and type II endoleaks, no
further treatment was performed. Intra-aneurysmal pres-
sure was monitored daily and indicated the pressure gener-
Fig 2. A, Intraoperative photograph of aneurysm creatio
to the posterior aspect of the prosthetic aneurysm by usi
exiting the anterior aspect of the aneurysm. B, Coronalated by untreated type II endoleaks.After endovascular exclusion of the aneurysm, intra-
aneurysmal pressure was determined continuously for 4
hours, and subsequently daily measurements were taken for
60 to 90 days, until the animal was killed. Systemic pressure
measurements from the aortic transducer were confirmed
by using a forelimb sphygmomanometer.
Implantation of PUF. The PUF (Biomerix, Rock-
ville, Md) used in this study is a biodurable, elastomeric
resilient foam (Fig 3). The implants used were press-cut
from a block of PUF, packaged into single-use peelable
pouches, and sterilized by -radiation. The implants are
configured as tapered cylinders in the range of 6.0 to 10.0
mm in diameter with a length of 1.0 cm. The material is
fully reticulated to minimize “window panes,” with a void
content of greater than 90% and pore sizes from 250 to 600
m.
PUF implants were introduced to fill the aneurysm sac
in a 1:1 volume ratio (14-25 implants were used for each
animal). Implants were individually loaded into a 7F deliv-
ery catheter for deployment. Four animals underwent treat-
ment of their type II endoleaks by using PUF implants to
induce endoleak thrombosis. The PUF was implanted into
the aneurysm sac at the time of stent-graft deployment. The
PUF was homogeneously distributed throughout the an-
eurysm sac by using the delivery system. The PUF is self-
expanding and filled the entire aneurysm sac external to the
stent graft.
The bilateral femoral arteries were exposed, and 9F
sheaths were introduced. Subsequently, 0.035-inch guide-
wires (Boston Scientific, Watertown, Mass) were posi-
tioned suprarenally via both femoral arteries. The ipsilateral
sheath was used to deploy the first 8-cm  5-mm PTFE
stent graft. The contralateral introducer sheath was placed
in the AAA sac outside the stent graft. Before deployment
of the second, distal 5-cm 8-mm stent graft, the 7F PUF
implant catheter was positioned in the aneurysm sac. The
implants were released after deployment of the second stent
graft to prevent distal embolization of any implants. Once
all the PUF implants were placed, the delivery catheter was
he lumbar arteries (yellow arrow) have been anastomosed
Carrel patch. The pressure-transducer cable can be seen
etic resonance angiogram before aneurysm exclusion.n. T
ng awithdrawn from the aneurysm sac. A completion angio-
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rysm and adequate distal runoff (Fig 4).
Radiologic imaging. At the time of endografting,
arteriography was performed to demonstrate patency and
direction of flow in the aneurysm side-branch arteries. At
the time of death, Doppler insonation and selective cannu-
lation of the side-branch arteries were performed, and
arteriography was performed to evaluate retrograde en-
doleak patency and to characterize the direction of flow in
the side-branch vessels and aneurysm sac.
Histologic and pathologic analysis. At the time of
death, the aorta was clamped proximally and distally to the
aneurysm. The specimen was perfusion-fixed at 100 mm
Hg in 3% glutaraldehyde buffered to pH 7.4 with sodium
cacodylate. The aneurysm, with the stent graft in place, and
implanted side-branch vessels were then removed en bloc
for gross and microscopic pathologic analysis (Fig 5). The
aneurysms were then sectioned longitudinally, and the
stent graft was removed. After dehydration in increasing
Fig 3. Polyurethane foam implant (Biomerix, Rockville
foam is extruded from the delivery catheter. The deliver
rods.
Fig 4. Intraoperative angiography during polyurethan
demonstrating placement of a PUF implant–loaded cath
Note the patent lumbar arteries (black arrows). The PU
(large white arrows).B,Completion angiogram demonst
flow from implanted lumbar arteries.concentrations of ethyl alcohol, representative sections ofthe aneurysm sac and side branches were imbedded in
paraffin. Longitudinal, transverse, and oblique sectioning
was performed, and microscopic analysis was performed
with hematoxylin and eosin stains.
Statistical analysis. All intra-aneurysmal pressure
measurements were indexed to the concurrently measured
systemic pressure and are reported as a ratio of intra-
aneurysmal pressure over systemic pressure; systemic arte-
rial pressure, therefore, has a value of 1.0. Analysis of the
three study groups was performed with analysis of variance
(ANOVA); post hoc analysis was performed with the
Scheffé test. Discrete variables were analyzed with 2 anal-
ysis. Statistical significance was assumed for P values .05.
RESULTS
Endoleak patency and flow assessment. Aneurysm
side-branch patency was confirmed by intraoperative an-
giography in all animals at the time of endovascular stent
graft placement. In all animals, complete exclusion from
) and delivery system. The self-expanding polyurethane
tem is composed of coaxially placed catheters and push
m (PUF) implantation. A, Intraoperative angiogram
(small white arrow) via the contralateral femoral artery.
y be visualized as filling defects within the aneurysm sac




ratingantegrade perfusion was achieved, and no type I or type III
eurysm
intra
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side branches demonstrated persistent side-branch and en-
doleak patency throughout the study period (60-90 days).
Retrograde endoleak patency was confirmed by intraoper-
ative arteriography, and Doppler insonation further con-
firmed endoleak patency at death.
In contrast, animals treated with PUF demonstrated
aneurysm thrombosis and no type II endoleak. Notably, an
immediate decrease in the amount of contrast pooling in
the aneurysm sac was seen as soon as the PUF was im-
planted. Arterial flow in the side branches and retrograde
aneurysm perfusion were confirmed to be absent by arte-
riography within 2 hours of implantation and at time of
death. Doppler insonation of the aneurysm side-branch
vessels further confirmed no arterial flow.
Intra-aneurysmal pressure. All data presented here
represent the average  SD for the entire postexclusion
period. After deployment of the stent graft, antegrade
aneurysm perfusion was eliminated, and intra-aneurysmal
pressure was significantly reduced within 3 hours in all
Fig 5. Gross specimen of polyurethane foam (PUF)-tr
Note the presence of thrombus amid the PUF in the an
Fig 6. Comparison ofanimals with type II endoleaks and stabilized within 48hours (intra-aneurysmal systolic pressure, 0.702  0.283;
mean pressure, 0.784  0.229; pulse pressure [PP], 0.406
 0.248; P  .001; Fig 6). After the initial decline in
intra-aneurysmal pressure, pressure measurements re-
mained stable throughout the study.
Control animals with aneurysms lacking implanted side
branches exhibited the lowest intra-aneurysmal pressure
ratio after exclusion from antegrade perfusion (systolic
pressure, 0.172  0.091; mean pressure, 0.137  0.102;
PP, 0.098  0.077). These values were statistically signifi-
cantly lower than pressures in aneurysms with patent type II
endoleaks by ANOVA with post hoc analysis (P  .001).
Intra-aneurysmal pressure was markedly reduced in
aneurysms treated with PUF as compared with aneurysms
with patent type II endoleaks (systolic pressure: PUF,
0.183  0.08; endoleak, 0.702  0.283; P  .001; mean
pressure: PUF, 0.142 0.09; endoleak, 0.784 0.229; P
 .001; PP: PUF, 0.054 0.04; endoleak, 0.406 0.248;
P  .001; P  .001 for comparison of all groups by
ANOVA). The intra-aneurysmal pressure in PUF-treated
aneurysm with the endovascular stent graft removed.
sac.
-aneurysmal pressures.eatedaneurysms was indistinguishable from control aneurysms
lin an
JOURNAL OF VASCULAR SURGERY
August 2005326 Rhee et althat had no endoleaks (systolic pressure: PUF, 0.183 
0.08; control, 0.172  0.091; mean pressure: PUF, 0.142
 0.09; control, 0.137  0.102; PP: PUF, 0.054  0.04;
control, 0.098  0.077; not significant by ANOVA and
Student t test). Intraoperative pressure measurements of
the aneurysm sac demonstrated a significant decrease in
pressure that corresponded to the cessation of contrast
pooling in the aneurysm sac by 2 hours after PUF implan-
tation.
Pathologic and qualitative histologic analysis.
Gross pathologic analysis confirmed the patency of the
side-branch vessels in aneurysms with untreated type II
endoleaks. Microscopic analysis of patent lumbar arteries
causing type II endoleaks demonstrated a widely patent
lumen lined by viable endothelial cells. Occlusion of the
side-branch vessels in aneurysms treated with PUF was also
confirmed by gross pathologic analysis. Lumbar artery side
branches from PUF-implanted aneurysms were microscop-
ically shown to have completely thrombosed; in addition,
thrombus was demonstrated throughout the aneurysm sac
and within the PUF implants (Fig 7). The characterization
of thrombus and deposition of fibrin in the aneurysm sac
found in PUF-treated aneurysms were both pathologically
and microscopically comparable to those of controls, which
had no endoleak.
DISCUSSION
Before successful clinical application of endovascular
AAA repair, animal models were extensively used and still
remain crucial to the development and understanding of
endovascular techniques. Initial animal studies evaluated
the feasibility of stent graft implantation and endovascular
aneurysm repair.25-27 Subsequently, animal models have
been used in several experimental designs, including evalu-
ation of endotension and characterization of en-
doleaks.28,29 These have provided further objective scien-
tific assessment of endovascular treatments of AAA.30-35
However, significant elements of endovascular repair of
AAA remain incompletely characterized by prior ex vivo
and animal model analysis.36-38
A variety of techniques have been designed to treat type
Fig 7. Photomicrograph of polyurethane foam (PUF)
inside of a prosthetic aneurysm (magnification, 40
illustrating incorporation of thrombus with red blood cel
cells within PUF (magnification, 100; stain, hematoxyII endoleaks, with varied results.39-43 Laparoscopic clip-ping of patent branch arteries has been described; however,
morbidity and failure rates are still unknown.44 Moreover,
amid reports of successful percutaneous coil embolization
of patent arteries, Solis et al39 reported a high failure rate
due to multiple anatomic mechanisms, such as retiform
endoleaks.
Direct injection of liquid embolic agents, such as
histoacryl glue and ethylene-vinyl alcohol copolymer,
has also been used to treat endoleaks by creating a
noncompressible cast of the aneurysm sac.42 The ra-
diopacity of the embolic agent itself, however, could
create a diagnostic challenge in surveillance imaging
studies. Application of the liquid embolic agents has also
been associated with embolization into downstream ves-
sels that leads to complications such as colonic ischemia
and paraplegia. Evaluation of the technical feasibility,
physiological dynamics, effect on intra-aneurysmal
pressure, and risk of rupture of this approach is ongoing.
The use of scaffolds for the treatment of type II en-
doleaks has been previously described by Walker et al,40,41
who used an absorbable gelatin sponge. Of the 48 patients
with an implanted thrombogenic sponge, 33 were available
for a mean follow-up of 4 months (range, 1-17 months),
during which no type II endoleaks were reported. Al-
though promising, the long-term durability of the gelatin
sponge and its effect on intra-aneurysmal pressure have yet
to be evaluated.
PUF offers significant potential advantages for the
treatment of type II endoleaks. The biocompatibility and
durability of PUF have been extensively researched and
proven by its various clinical applications, ranging from
heart valves to facial reconstruction implants. Its morphol-
ogy has made it an attractive implantable material because
of its unique, reticulated architecture, which is character-
ized by an open-celled, porous structure. The intercon-
nected network of pores permits cellular ingrowth and
proliferation throughout the pores of the implant, thus
facilitating vascularized tissue ingrowth and thrombus for-
mation. PUF can also be engineered to vary pore size, void
content, and implant shape for optimization thromboge-
nicity and tissue integration. These benefits may provide a
ed aneurysm. A, Thrombus within PUF (black arrow)
n, hematoxylin and eosin). B, Higher magnification
blood cell fragments, fibrin, and occasional white blood
d eosin).-treat
; stai
ls, redsafe, durable treatment option for type II endoleaks.
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pressure transducer to evaluate the effectiveness of PUF for
inducing type II endoleak thrombosis and the effect of PUF
treatment on intra-aneurysmal pressure. In the model an-
eurysms with persistently patent type II endoleaks, intra-
aneurysmal pressure was maintained at greater than 70% of
systemic pressure. This level of intra-aneurysmal pressure
seems significant, although further studies will be necessary
to adequately characterize its clinical effect and implica-
tions. In contrast, aneurysms with type II endoleaks treated
with PUF had nearly complete elimination of intra-
aneurysmal pressures. The intra-aneurysmal pressure after
PUF treatment was at less than 20% of systemic pressure.
These pressures were equal to the intra-aneurysmal pres-
sure in control animals that had aneurysms with no side
branches and no endoleaks. Of note in this model, only two
lumbar vessels contributed to the endoleak. In the clinical
situation, multiple arterial side branches may be present,
and this may complicate treatment. Treatment with PUF
may be considered after the development of a type II
endoleak. Theoretically, this could be accomplished by
direct translumbar access of the aneurysm sac after stent
graft deployment. Alternatively, prophylactic use may be
considered at the time of endovascular treatment. The PUF
could potentially be implanted to prevent endoleak forma-
tion. Clinical application of PUF to larger aneurysms will
await the results of clinical trials.
Characterization of the intra-aneurysmal thrombus in
animals with multiple arterial side branches treated with
PUF demonstrated significant incorporation of thrombus
within the reticulated architecture and void content of the
foam. Histologic characterization of thrombus created by
PUF has been previously studied by Kipshidze et al.45 In
this study, porcine iliac arterial occlusion was achieved by
PUF implantation, which resulted in organizing fibrin/
platelet-rich thrombus formation with chronic inflamma-
tion that consisted of macrophages, lymphocytes, and
giant-cell reaction at 1 month. These findings, along with
our results, suggest that thrombus deposition in PUF may
be physiologically similar to naturally occurring thrombus,
although more extensive studies will be necessary to more
completely characterize PUF-induced thrombosis.
It is important to note that significant differences exist
between the canine and the human coagulation system,
and, therefore, data should be interpreted and compared
with caution. However, without established clinical signif-
icance of type II endoleaks and its various treatment op-
tions, it may be prudent to thoroughly evaluate these issues
in animal models before clinical application.
CONCLUSIONS
In the canine model, placement of PUF into the aneu-
rysm sac to treat type II endoleaks results in thrombosis of
the aneurysm sac, type II endoleak, and arterial side
branches with the nearly complete elimination of arterial
intra-aneurysmal pressure. Cellular infiltration into the
PUF may create physiologically stable and durable correc-
tion of type II endoleaks. Further studies are necessary toassess the potential clinical application of PUF as a treat-
ment modality.
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